| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jami Kronick, Manal Y Gabril, Andrew A Hous. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2023-08-02. PMID:37532078. |
microscopic kidney disease in tuberous sclerosis complex and treatment with mtor inhibition. |
2023-08-02 |
2023-08-14 |
Not clear |
| Marjan Taherian, Paria Bayati, Mohammad-Ali Assarehzadegan, Mansoureh Soleimani, Hadi Poormoghim, Nazanin Mojtabav. Insights into Overlappings of Fibrosis and Cancer: Exploring the Tumor-related Cardinal Genes in Idiopathic Pulmonary Fibrosis. Iranian journal of allergy, asthma, and immunology. vol 22. issue 2. 2023-07-27. PMID:37496412. |
gene expression analyses indicated a significant elevation of regulatory associated protein of mtor (raptor), ras homolog enriched in brain (rheb), s6 kinase 1, and eukaryotic translation initiation factor 4e-binding protein 1 (4ebp1), as well as a significant reduction of vegfa, tuberous sclerosis complex (tsc2), and lrp1; no changes were observed in the tsc1 mrna level. |
2023-07-27 |
2023-08-14 |
mouse |
| Aline Grosskopf Monich, Mariana Faucz Munhoz da Cunha, Fellype Carvalho Barret. mTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis. Jornal brasileiro de nefrologia. 2023-07-27. PMID:37497829. |
mtor inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis. |
2023-07-27 |
2023-08-14 |
Not clear |
| Kellen D Winden, Truc T Pham, Nicole A Teaney, Juan Ruiz, Ryan Chen, Cidi Chen, Mustafa Sahi. Increased degradation of FMRP contributes to neuronal hyperexcitability in tuberous sclerosis complex. Cell reports. vol 42. issue 8. 2023-07-26. PMID:37494191. |
tuberous sclerosis complex (tsc) and fragile x syndrome are associated with alterations in the mechanistic target of rapamycin (mtor) and fragile x messenger ribonucleoprotein 1 (fmrp), which have been implicated in the development of asd. |
2023-07-26 |
2023-08-14 |
human |
| Wencheng Fu, Geng W. Design of negative-regulating proteins of Rheb/mTORC1 with much reduced sizes of the tuberous sclerosis protein complex. Protein science : a publication of the Protein Society. 2023-07-18. PMID:37462942. |
the tuberous sclerosis protein complex (tscc) is a master negative regulator of the mtorc1 signaling pathway through hydrolyzing the gtp loaded on the small gtpase rheb, which is a key activator of mtor. |
2023-07-18 |
2023-08-14 |
human |
| Saygın Yıldırım, Ebru Aypar, Burça Aydın, Canan Akyüz, Hayrettin Hakan Aykan, İlker Ertuğrul, Tevfik Karagöz, Dursun Aleha. Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment. The Turkish journal of pediatrics. vol 65. issue 3. 2023-07-03. PMID:37395967. |
everolimus, a mechanistic target of rapamycin (mtor) inhibitor, can be used in the treatment of rhabdomyomas seen in tuberous sclerosis complex. |
2023-07-03 |
2023-08-14 |
Not clear |
| Simone Bonazzi, Audrey Gray, Noel M Thomsen, Jonathan Biag, Nancy Labbe-Giguere, Erin P Keaney, Hasnain A Malik, Yingchuan Sun, Jill Nunez, Rajeshri G Karki, Mark Knapp, Robert Elling, John Fuller, Gwynn Pardee, Lucas Craig, Ketthsy Capre, Sarah Salas, Aakruti Gorde, Guiqing Liang, Danuta Lubicka, Stephanie M McTighe, Carleton Goold, Shanming Liu, Lin Deng, Jin Hong, Alexander Fekete, Pascal Stadelmann, Wilfried Frieauff, Azeddine Elhajouji, Daniel Bauer, Andreas Lerchner, Branko Radetich, Pascal Furet, Grazia Piizzi, Doug Burdette, Christopher J Wilson, Stefan Peukert, Lawrence G Hamann, Leon O Murphy, Daniel Curti. Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes. Journal of medicinal chemistry. 2023-07-03. PMID:37399505. |
the allosteric inhibitor of the mechanistic target of rapamycin (mtor) everolimus reduces seizures in tuberous sclerosis complex (tsc) patients through partial inhibition of mtor functions. |
2023-07-03 |
2023-08-14 |
Not clear |
| Aishwarya Ramamurthy, Gemma Louise Carvil. Raptor Preys on mTOR Imbalance in Tuberous Sclerosis. Epilepsy currents. vol 23. issue 3. 2023-06-19. PMID:37334409. |
raptor preys on mtor imbalance in tuberous sclerosis. |
2023-06-19 |
2023-08-14 |
Not clear |
| Elisabetta Chiaradia, Ingrid Miller, Giovanni Renzone, Alessia Tognoloni, Alice Polchi, Federico De Marco, Brunella Tancini, Andrea Scaloni, Alessandro Magin. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells. Journal of proteomics. 2023-05-19. PMID:37207814. |
significance: tuberous sclerosis complex (tsc) is a multisystemic disorder caused by inactivating mutations of tsc1 or tsc2 genes, which induce overactivation of the mtor component. |
2023-05-19 |
2023-08-14 |
Not clear |
| Uchenna Unachukwu, Jarrod Sonett, Denzel Woode, Takayuki Shiomi, Kiran Chada, Jeanine M D'Armient. Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model via induction of Apoptosis. Molecular cancer therapeutics. 2023-05-01. PMID:37127876. |
tuberous sclerosis complex (tsc) tumors are presently incurable despite a cytostatic response to mtor pathway inhibition since recurrence of disease occurs after discontinuation of treatment. |
2023-05-01 |
2023-08-14 |
mouse |
| Dominika Śmiałek, Katarzyna Kotulska, Aleksandra Duda, Sergiusz Jóźwia. Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age. Neurology and therapy. 2023-04-21. PMID:37085686. |
effect of mtor inhibitors in epilepsy treatment in children with tuberous sclerosis complex under 2 years of age. |
2023-04-21 |
2023-08-14 |
Not clear |
| Dominika Śmiałek, Katarzyna Kotulska, Aleksandra Duda, Sergiusz Jóźwia. Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age. Neurology and therapy. 2023-04-21. PMID:37085686. |
mechanistic target of rapamycin (mtor) inhibitors sirolimus and everolimus are an effective therapy for subependymal giant cell astrocytomas, cardiac rhabdomyomas, renal angiomyolipomas, and lymphangioleiomyomatosis associated with tuberous sclerosis complex (tsc). |
2023-04-21 |
2023-08-14 |
Not clear |
| Lijun Lv, Jiyu Guan, Ruixue Zhen, Pin Lv, Mengshi Xu, Xingyuan Liu, Shishi He, Ziyu Fang, Zi Li, Yungang Lan, Huijun Lu, Wenqi He, Feng Gao, Kui Zha. Orf virus induces complete autophagy to promote viral replication via inhibition of AKT/mTOR and activation of the ERK1/2/mTOR signalling pathway in OFTu cells. Veterinary research. vol 54. issue 1. 2023-03-15. PMID:36918891. |
moreover, orfv-induced autophagic activity was found to rely on an increase in the phosphorylation of tuberous sclerosis complex 2 (tsc2) and a decrease in the phosphorylation of mammalian target of rapamycin (mtor), which is mediated by the suppression of the pi3k/akt/mtor signalling pathway and activation of the erk1/2/mtor signalling pathway. |
2023-03-15 |
2023-08-14 |
Not clear |
| S Auvin, S Baula. mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations. Revue neurologique. 2023-03-11. PMID:36906459. |
mutations of mtor pathway genes are involved in tuberous sclerosis complex (tsc) as well as in a range of cortical malformations from hemimegalencephaly (hme) to type ii focal cortical dysplasia (fcd ii), leading to the concept of "mtoropathies" (mtor pathway-related malformations). |
2023-03-11 |
2023-08-14 |
mouse |
| Seth Bernacki, Paarth Dodia, Mikél Elizabeth Muse, Luke Maxfiel. Cutaneous Manifestations of Sarcoidosis Seen in a Patient with a History of Tuberous Sclerosis. Case reports in dermatology. vol 15. issue 1. 2023-02-23. PMID:36817851. |
there may be a shared dysfunction of mtor present in sarcoidosis and tuberous sclerosis. |
2023-02-23 |
2023-08-14 |
Not clear |
| Dominika Śmiałek, Sergiusz Jóźwiak, Katarzyna Kotulsk. Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age-A Bicenter Retrospective Study. Journal of clinical medicine. vol 12. issue 1. 2023-01-08. PMID:36615165. |
mtor inhibitors are a novel pharmacotherapy recommended for subependymal giant astrocytomas, refractory epilepsy, and the treatment of the other clinical manifestations of tuberous sclerosis complex (tsc). |
2023-01-08 |
2023-08-14 |
Not clear |
| D Farges, N Sigg, D Ville, L Marti. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. vol 29. issue 5S. 2022-12-30. PMID:36585067. |
use of mtor inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex. |
2022-12-30 |
2023-08-14 |
Not clear |
| Kuriko Kagitani-Shimono, Hiroki Kato, Fumihiko Soeda, Yoshiko Iwatani, Masashi Mukai, Katsuhiro Ogawa, Koji Tominaga, Shin Nabatame, Masako Taniik. Extension of microglial activation is associated with epilepsy and cognitive dysfunction in Tuberous sclerosis complex: A TSPO-PET study. NeuroImage. Clinical. vol 37. 2022-12-15. PMID:36521371. |
tuberous sclerosis complex (tsc) is a condition that results in the overactivation of the mammalian target of rapamycin (mtor) pathway, which has been linked to the activation of microglia responsible for neuroinflammation. |
2022-12-15 |
2023-08-14 |
Not clear |
| Chen-Xi Zhang, Kai-Feng Xu, Qin Long, Xiao Zhang, Zhi-Kun Yang, Rong-Ping Dai, Zhi-Qiao Zhan. Long-term efficacy and safety of sirolimus for retinal astrocytic hamartoma associated with tuberous sclerosis complex. Frontiers in cell and developmental biology. vol 10. 2022-12-05. PMID:36467422. |
mammalian target of rapamycin (mtor) inhibitors (sirolimus or everolimus) have been demonstrated effective in reducing the size of tuberous sclerosis complex (tsc)-associated retinal astrocytic hamartoma (rah) in short term. |
2022-12-05 |
2023-08-14 |
Not clear |
| Shengzhao Hu, Yingli Chen, Shipeng Huang, Min Liu, Ying Liu, Shaofang Huan. Sodium Danshensu protects against oxygen glucose deprivation/reoxygenation-induced astrocytes injury through regulating NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome and tuberous sclerosis complex-2 (TSC2)/mammalian target of rapamycin (mTOR) pathways. Annals of translational medicine. vol 10. issue 20. 2022-11-17. PMID:36388798. |
sodium danshensu protects against oxygen glucose deprivation/reoxygenation-induced astrocytes injury through regulating nod-like receptor pyrin domain containing 3 (nlrp3) inflammasome and tuberous sclerosis complex-2 (tsc2)/mammalian target of rapamycin (mtor) pathways. |
2022-11-17 |
2023-08-14 |
Not clear |